[1] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[2] |
LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo.
Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
|
[3] |
LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping.
Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
|
[4] |
DU Ying, XIE Yanming, WANG Lianxin, GENG Hongjiao, LI Xiangjie.
Clinical characteristics and drug combination analysis of Lianhua Qingwen capsules (granules) in the real world
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 296-300.
|
[5] |
WANG Yu, HUANG Jingyi, HOU Lixin, LI Shuang, CUI Yongkang, HUANG Lanwei.
Humoral immune characteristics of peripheral blood of CAP patients with antibiotic-associated DILI
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 132-135.
|
[6] |
JIANG Jiandong.
Development and clinical safety of paediatric medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 1-6.
|
[7] |
HOU Tiantian, MA Sisi, WU Xiaobing, HUO Guitao, PAN Dongsheng, WANG Chao, XIA Yan, LIU Yi, ZHOU Xiaobing, LIU Guoqing, GENG Xingchao.
Toxicity of gene therapy drug AAV5-LPLS447X in mice
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 19-26.
|
[8] |
HOU Tiantian, XIA Yan, PAN Dongsheng, HUO Guitao, MA Xuemei, LIU Ziyang, SUN Li, LIU Yi, YAN Jian'ao, WU Xiaobing, ZHOU Xiaobing, LIU Guoqing, GENG Xingchao.
Toxicity of gene therapy drug AAV5-LPLS447X (GC304) in cynomolgus monkeys
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 27-33.
|
[9] |
DONG Hanshuo, SUN Li, ZHAO Xiaoxiao, WANG Lianxin, YU Xiaokang, XIE Yanming.
Clinical characteristics and drug combination analysis of elemene injectable emulsion in the elderly in the real world
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 845-850.
|
[10] |
WANG Juli, ZHANG Xiaomeng, ZHANG Bing, LYU Jintao.
Safety of medications for cardiovascular diseases in community clinics
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 744-748.
|
[11] |
YANG Fan, MA Haiping, YOU Mengru, LIAO Sha, LIU Lan, ZHU Jun.
Applications of antiviral drugs in 456 patients with COVID-19
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 413-416.
|
[12] |
SUN Chunquan, XIE Yanming, HOU Hengyue.
Data mining of clinical characteristics and combined medications of 4 832 patients with heart failure treated with Shengmai injection
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 130-133.
|
[13] |
CHENG Xu, ZHANG Lidan, XIE Yanming, GAO Yang, YANG Yunyun.
Complex network analysis of combined medications of Danshen Ligustrazine injection in the treatment of coronary heart disease complicated with hypertension
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1325-1331.
|
[14] |
LI Lingjun, TAO Lei, WEI Jun, LI Hongyang, CAI Baole, MA Pengcheng.
Effects of a single oral administration of finasteride tablets on bilirubin levels
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1202-1205.
|
[15] |
HUANG Liting, TANG Zaixiang, BAI Lu, SHI Guanhong, JIANG Yiguo.
Adverse reactions of benzodiazepines based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1223-1227.
|